ASTRIA THERAPEUTICS INC (ATXS) Stock News

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Astria Therapeutics (NASDAQ:ATXS) just reported results for the second quarter ...

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024

ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Mentions: AVGR KALV ATNF ANEB ...

Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Mentions: ANGO TPC VHI LMNR ...

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Bradykinin Symposium

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update